US 7037706

I'll search for authoritative information on this specific patent number.

Let me look for the claim text and any CAFC/litigation records.

Let me try to retrieve the actual independent claim text and check for any litigation involving this patent.

US Patent 7,037,706 — Verification Summary

Important identifier note first: the string "7037706" also appears in the wild as an unrelated Japanese patent number (JP 7037706, a reconfigurable bipedal robot), an unrelated Brazilian municipal contract number, a Lithuanian insolvency notice, and a Korean application figure label. None of those are the document below. The record here is specifically US 7,037,706 B1.

Bibliographic data (verified)

Family members noted on the record: continuation US 11/187,989 → US 7,517,643 B2, and US 12/395,311 → US 2009/0233808 A1.

Abstract

The verbatim abstract text was not captured in the source I retrieved from Google Patents (the fetch returned the specification/definitions but not the abstract field). Rather than paraphrase it as if it were the abstract, here is the substance as stated in the patent's own Summary of Invention:

Replicable genetic packages to which a wide variety of compounds are attached are provided. These packages can be used to rapidly screen large libraries of compounds to identify compounds with a desired activity. Some packages harbor a nucleic acid tag encoding a characteristic of the compound(s) borne by the package, which tag can be used to identify active compounds. Certain packages display a compound other than a polypeptide and harbor a heterologous nucleic acid tag that encodes a characteristic of the compound.

Field: combinatorial chemistry and drug discovery. The stated problem being solved is the limitation of conventional phage display, which "is only applicable to display of peptides," whereas many effective drugs are small organic molecules.

Independent claims — plain-language overview

The full claim set was not retrieved verbatim; the independent claims I could ground on the record are claims 1, 36, and 41.

Claim 1 — A bacteriophage displaying a non-peptide compound, with a decodable DNA tag.
Verbatim text not retrieved. Reconstructed from the dependent claims (2–35), which all read "The bacteriophage of claim 1, wherein…", its scope is: a bacteriophage that displays a compound other than a polypeptide expressed by the bacteriophage, and that contains a heterologous nucleic acid tag which can be decoded to identify a characteristic of that compound, where the tag is a nucleic acid segment other than a segment encoding a polypeptide displayed on the bacteriophage. (Dependent claim 7 adds the caveat that if the compound is a peptide, it must be attached by other than a peptide linkage — i.e., the core case is non-peptidic chemistry.) Various dependents cover: linker-mediated attachment (claims 9–11), binding-pair linkers such as biotin/avidin-streptavidin-neutravidin or antibody/hapten (12–17), multiple displayed compounds (20–31), and tag semantics — tag encodes the compound's identity (32) or an assigned value/symbol (33).

Claim 36 — A collection (library) of such bacteriophages. (Verbatim:)

"A collection of bacteriophages, each displaying a compound other than a polypeptide expressed by the bacteriophage and comprising a heterologous nucleic acid tag that can be decoded to identify a characteristic of the compound, and the heterologous nucleic acid tag is a nucleic acid segment other than a segment that encodes for a polypeptide displayed on the bacteriophage and wherein at least some of the bacteriophage display different compounds and bacteriophages displaying different compounds harbor different tags."

Plain language: a library of phage, each carrying a chemically attached (non-genetically-encoded) compound and a separate DNA barcode that identifies which compound it is, with different phage carrying different compounds and different barcodes. Claim 37 limits the tags to isothermal tags (same base composition).

Claim 41 — A bacteriophage where the compound is attached through a linker. (Verbatim:)

"A bacteriophage displaying a compound other than an expressed polypeptide, wherein the bacteriophage and the compound are attached via a linker, and wherein the bacteriophage comprises a heterologous nucleic acid tag that can be decoded to identify a characteristic of the compound and the heterologous nucleic acid tag is a nucleic acid segment other than a segment that encodes for a polypeptide displayed on the bacteriophage."

Plain language: same concept as claim 1, but narrowed to compounds joined to the phage by a linker (covalent or binding-pair mediated, as elaborated in FIG. 1's streptavidin/biotin example and later dependents).

Claim numbering caveat: the specification's Summary of Invention also describes screening/assay methods (assaying packages to find a desired property, then decoding the tag; in vitro transwell and in vivo transport assays). Those are almost certainly claimed as additional independent method claims, but I could not verify their claim numbers or wording, so I am not stating them as independent claims here.

Litigation / CAFC 2026 docket status

• No CAFC 2026 docket, and no district court action, was found naming US 7,037,706. Searches of Federal Circuit 2026 activity surfaced only unrelated matters (e.g., Hafeman v. Google, V.O.S. Selections v. Trump, Masimo v. Apple, the Newman judicial-suspension dispute) — none reference this patent.
• Google Patents' litigation field for this patent is empty, consistent with no recorded assertions.
• The patent is expired for failure to pay maintenance fees (adjusted expiration January 20, 2023), which independently makes live 2026 enforcement unlikely.

Confidence and limitations

• High confidence: patent number, title, app number, filing/priority/issue dates, inventors, assignee, and expiry status — these are consistent across Google Patents, Justia, and FreePatentsOnline.
• High confidence: the verbatim text of claims 36 and 41 as quoted above.
• Lower confidence (explicitly flagged): the verbatim abstract, the verbatim wording of claim 1, the total claim count, and whether any method claims beyond claim 41 are independent. I could not retrieve the full claim set, so treat the Claim 1 reconstruction as inference from its dependents rather than a quotation.
• The closest substantive enabling publication by the inventors is Woiwode et al., "Synthetic compound libraries displayed on the surface of encoded bacteriophage," Chemistry & Biology 10(9):847–858 (Sep. 2003), cited on the face of the record.

I'll research litigation involving US patent 7037706 across litigation databases.

Initial searches show results that are unrelated (a Venezuelan court docket number, a Japanese patent, a Brazilian municipal contract). Let me search more specific litigation sources.

No litigation has surfaced. Let me check the dedicated litigation databases directly.

Litigation Search Results — U.S. Patent No. 7,037,706

Bottom line: I found no evidence of any litigation involving U.S. Patent No. 7,037,706.

What I searched

I ran targeted queries against general web indexes that surface patent-litigation content (Unified Patents portal references, CourtListener/RECAP dockets, Justia dockets, PTAB filings, RPX/insight material, and district-court complaints), using the exact identifiers 7037706, 7,037,706, and associated party names (XenoPort, Barrett, Dower, Gallop, Woiwode, Cwirla, "replicable genetic packages").

What I found (all false positives, none about this patent)

Every hit for the literal string "7037706" traced to something else:

Nothing tied to US 7,037,706 (Barrett et al., "Compounds displayed on replicable genetic packages and methods of using same," filed 2000-09-29, granted 2006-05-02, assignee XenoPort, Inc.) appeared as a patent-in-suit, IPR/PGR/CBM subject, ITC respondent patent, or reexamination dispute.

Status context for the patent

• Legal status: Expired – Fee Related; adjusted expiration date 2023-01-20 (per the Google Patents record).
• Continuity noted in the record: related filings US 11/187,989 (publication US 7517643B2) and US 12/395,311 (publication US 20090233808A1) list priorities tied to this family — these are prosecution-family links, not litigation.

Important caveats (please read)

1. I could not directly query the Unified Patents litigation caselist (portal.unifiedpatents.com/litigation/caselist) or PACER/CourtListener docket databases with a structured search in this session; my conclusion rests on web-index searches. It is possible a suit exists that is not well-indexed.
2. I did not identify any CAFC appeal, ITC Section 337 investigation, PTAB post-grant proceeding, or ex parte/inter partes reexamination involving this patent.
3. XenoPort, Inc. (now part of Arbor Pharmaceuticals/American Stockholder entities and formerly partnered with GSK) appears in SEC filings discussing IP enforcement, but I found no reference connecting it to enforcement of the '706 patent.

Recommended verification steps

To obtain a definitive negative or positive, run the exact number against:

• Unified Patents portal: https://portal.unifiedpatents.com/litigation/caselist?patents=7037706
• CourtListener/RECAP: search docket databases for "7,037,706"
• USPTO Patent Center / PTAB: the patent's "Litigation" and "Post-Grant" tabs, plus the USPTO Patent Litigation Docket Report (per 35 U.S.C. § 290 filings)
• Westlaw KeyCite / Lexis CourtLink for a formal litigation-history report

Conclusion: Based on available search results, no litigation is known involving U.S. Patent No. 7,037,706. I am stating this as a search-based finding, not a certified database clearance; a PACER/CourtListener and Unified Patents portal query should be run to confirm the null result before relying on it.

I'll start by confirming the structured data and then search for any PTAB activity on this patent number.

Let me run additional targeted searches to make sure nothing has been indexed outside the ODP.

One more pass to check for litigation/reexam angles that might imply PTAB filings.

PTAB Proceedings — US Patent 7,037,706 B1

Methodology / confidence note. The canonical list in the structured "PTAB proceedings on file" block for this patent is empty — the USPTO Open Data Portal returns no AIA trial proceedings as of the most recent ingest. I ran four independent web searches (patent number, patent owner, petitioner-side phrasing, and docket/aggregator phrasing) to catch anything the ODP may not have indexed. Nothing surfaced. The only near-matches the search returned were proceedings on different patents — I list them below so you don't mistake them for this one. I do not have access to a live PTAB E2E query in this session, so I cannot affirmatively certify that no petition was filed in the last few weeks; everything below is grounded in the record I could actually retrieve.

Proceedings overview

Total AIA trial proceedings on US 7,037,706: 0. There is no IPR, no PGR, and no CBM. Accordingly there is no breakdown by status to report — no claims invalidated, no claims sustained on the merits, no settlements, no institution decisions. The bottom line for a defendant is not "the patent is hardened" in the sense of having survived an IPR; it is that the PTAB has never tested a single claim of this patent, and — far more importantly — the patent is no longer in force: the record shows legal status "Expired – Fee Related," with an adjusted expiration date of 2023-01-20. The absence of PTAB activity here is not a strength signal so much as a consequence of the patent having expired before the AIA-trial era of heavy biotech/pharma IPR use caught up with it.

Proceedings

None — no PTAB proceeding is on file for US 7,037,706

• Type: n/a
• Filed: n/a
• Status: n/a (no proceeding exists)
• Judge panel: n/a
• Petition grounds: n/a
• Institution decision: n/a
• Final Written Decision: n/a
• Settlement / termination: n/a
• Appeal: n/a
• Defensive value: A defendant does not get a ready-made invalidity judgment, but also does not face § 315(e)(2) estoppel from anyone else's IPR, because no IPR exists. The operative defensive fact is patent expiry: per the sources below, the patent's adjusted expiration is 2023-01-20 and its status is Expired – Fee Related. Verify that independently before relying on it, but if it holds, the assertion exposure is limited to past damages (and, under 35 U.S.C. § 286, at most the six years preceding the complaint) — an infringement theory built on ongoing or future sales would have a lifespan problem on its face.

Record links for the expiration/status facts:

• Google Patents, US7037706B1 — https://patents.google.com/patent/US7037706/en (filing 2000-09-29; priority 1999-09-29; granted 2006-05-02; "Adjusted expiration 2023-01-20"; "Expired – Fee Related")
• USPTO Patent Center — https://patentcenter.uspto.gov/ (search application 09/675,525 for the authoritative maintenance-fee and status history)
• USPTO Assignment record — XenoPort, Inc. assignment recorded 2001-05-11 (inventors Barrett, Dower, Gallop, Woiwode, Cwirla → XenoPort, Inc.)

Near-miss proceedings (NOT this patent — do not cite as 7,037,706 activity)

These appeared in keyword searches and are different patents. I flag them because a number-collision error is easy to make:

• IPR2017-00809 — petitioner briefing captioned to U.S. Patent No. 6,703,106. Note the transposition: 6,703,106 vs. 7,037,706. Not related to this patent on the face of the documents retrieved.
• CBM2016-00062 — Covered Business Method review of U.S. Patent No. 6,771,970. Unrelated.
• IPR2020-01226 — Cisco Systems, Inc. v. Monarch Networking Solutions LLC, U.S. Patent No. 8,130,775 B2. Unrelated; appeared only because of § 314(a)/Fintiv citation text.

I found no litigation docket in which 7,037,706 is the asserted patent, and no Unified Patents (or other defensive-aggregator) reexamination or IPR naming it.

Strategic summary

Claim-by-claim status. No claim of 7,037,706 has been canceled by the PTAB, and none has been sustained by the PTAB. Every claim stands exactly as issued on 2006-05-02 — i.e., all claims are UNTESTED in any AIA trial. (The printed patent carries at least 34 claims — the search results show claims 32, 33 and a truncated claim 34 in the bacteriophage genus — but I did not verify the total claim count and am not going to guess at it.) Critically, "untested" is not the same as "strong." This is a 2000-priority application in a crowded art (phage display, biotin/streptavidin capture, chemically conjugated non-peptide libraries) whose own specification cites Cwirla 1990, Devlin 1990, Scott & Smith 1990, and Ladner et al. U.S. Pat. Nos. 5,403,484 / 5,571,698 / 5,723,598 / 5,958,703 / 6,309,842 / 6,777,239 — i.e., the Dower/Ladner family that largely pre-dates it. A well-funded invalidity case has substantial raw material; it simply has never been run at the Board.

Estoppel landscape. Because there is no IPR or PGR on this patent, 35 U.S.C. § 315(e)(2) estoppel has never attached against anyone. No petitioner, and no privy of any petitioner, is barred from raising any § 102/§ 103 ground in district court. Conversely, a defendant cannot borrow another party's invalidity work product or an institution decision, because none exists. There is also no IPR-time-bar calculus (§ 315(b)) and no Fintiv discretionary-denial risk to plan around, because there is nothing to file against in a trial that would overlap a pending case. Practically, this means the full prior-art universe is available — including the patent's own cited references and the Dower/Ladner family — with no estoppel ceiling.

Pattern signals. No repeat petitioner pattern (there is no petitioner). No patent-owner appeal activity to the Federal Circuit from any Board decision on this patent, because there has been no Board decision. No defensive aggregator in the chain. The only structural signal worth noting is prosecution-side: the 843-day patent term adjustment under § 154(b) pushed the term out, but the patent still reached expiry by 2023-01-20 per the record — so the enforcement window has closed regardless of how the invalidity merits would have come out. Related family members exist and were not examined here: US 7,517,643 B2 (via application 11/187,989, priority link recorded 2005-07-22) and US 2009/0233808 A1 (via application 12/395,311). I did not find PTAB activity on those either, but I ran no dedicated search on them, so treat that as unverified and worth a separate check if the family is relevant to you.

Recommended next steps

1. If you are a defendant and no claim is invalidated, do not expect a PTAB shortcut — and do not expect a PTAB threat either. There is no FWD to quote and no institution decision to distinguish, because no proceeding exists. Any statement in a demand letter implying PTAB history, a surviving-IPR narrative, or "validated claims" would be unsupported by the record.
2. Pin down enforceability before anything else. Confirm on USPTO Patent Center (application 09/675,525) whether the "Expired – Fee Related" status and the 2023-01-20 adjusted expiration on the Google Patents record reflect actual end-of-term expiry. If the patent is expired, the practical assertion envelope collapses to past damages subject to the § 286 six-year lookback measured from the complaint date, plus any pre-expiry marking/notice issues under § 287. That is usually a case-killer for a plaintiff, and it is a cheaper defense to develop than an invalidity case.
3. If your exposure is to pre-2023-01-20 conduct and the number is material, build the invalidity case anyway — filing options are narrower than you'd think. A patent that has already expired cannot be amended in ex parte reexamination (no claim amendments are permitted for expired claims), and an IPR against an expired patent is generally permitted but of limited practical value because there is nothing left to cancel prospectively. The realistic venues are district court invalidity (no estoppel, full art available) and a declaratory judgment of invalidity/non-infringement if you have standing. Before filing anything, verify the current status on PTAB E2E — https://ptab.uspto.gov/ — and the district court docket on CourtListener — https://www.courtlistener.com/ — because I could not run a live query and cannot exclude a very recently filed petition that the ODP has not yet ingested.
4. Do a separate activity check on the family (US 7,517,643; US 2009/0233808) if the patent owner or its successors hold them, since a live continuation could reset your exposure even where the '706 patent is expired.

Constraints observed: no proceeding numbers were invented; no claim numbers were attributed to any decision, because no decision exists; all dates are YYYY-MM-DD. Where I could not verify something (total claim count, family-member PTAB history, the exact basis of expiry), I have said so rather than filling the gap.

I'll start by checking the authoritative record and any indexed assignment data for this patent.

Let me dig into the assignment record and the corporate history of the original assignee.

Let me check Plainsite/assignment databases for the specific XenoPort recording and the inventors' employment history.

Assignment & Ownership Analysis — US 7,037,706 B1 ("Compounds displayed on replicable genetic packages and methods of using same")

Application 09/675,525 · filed 2000-09-29 · priority US 60/156,675 (1999-09-29) · issued 2006-05-02 · 48 claims · term extended 843 days (35 U.S.C. 154(b))

Evidence caveat up front. I was able to retrieve the patent front page, Google Patents legal events, and SEC materials, but my searches did not return the Assignment Center record detail page for this patent. As a result I have one confirmed recording (the original inventor→company assignment) but no reel/frame, no execution date, and no recorded correspondent. I have not supplied placeholder numbers for any of those fields. Everything below is limited to what the retrieved sources actually show.

Inventors

Prior affiliation (context, not from the assignment record). The patent's own background cites Cwirla, Barrett and Dower's 1990 PNAS paper "Peptides on phage: a vast library of peptides for identifying ligands" (87:6378–6382), which was Affymax Research Institute (Palo Alto) work; Dower and Cwirla authored the foundational Affymax phage-display patents, and Gallop and Woiwode were also part of the Affymax combinatorial-chemistry group. XenoPort was founded in 1998 out of that milieu and took the combinatorial/transporter platform with it. I am confident about the Affymax provenance for Barrett, Dower and Cwirla; for Gallop and Woiwode I rate it likely but unverified in this session.

Unusual-pattern check — no departure cluster found. The classic red flag (all inventors gone within 12 months, preceding a fire-sale) is not supported. A separate XenoPort recording (US 7,183,259, "Amino acid conjugates providing for sustained systemic concentrations of GABA analogues") shows Barrett and Gallop still executing assignments to XenoPort on 2003-04-25, recorded 2003-05-13 at reel 14069/164 — nearly three years after this filing. That is evidence of retained inventors, not a mass exodus.

Original assignee

XenoPort, Inc., a Delaware corporation, Palo Alto, CA at issue; later Redwood City, CA. Front-page assignee: "Xenoport, Inc., Palo Alto, CA (US)." Public since its 2005 IPO (Nasdaq: XNPT, SEC CIK 0001130591, SIC 2834).

• Primary line of business: clinical-stage/specialty biopharmaceuticals. Its platform was carrier-mediated transport prodrugs, and its commercial product was HORIZANT (gabapentin enacarbil), approved in the US for restless legs syndrome and postherpetic neuralgia; REGNITE (gabapentin enacarbil ER) was marketed in Japan by Astellas.
• Did it ship a product embodying the claims? No. The claims are directed to compound-bearing replicable genetic packages (phage/bacteria/spores displaying non-polypeptide compounds with nucleic-acid tags) — a combinatorial-chemistry research platform, legacy Affymax-adjacent technology. It is not the prodrug/transporter chemistry behind HORIZANT. XenoPort prosecuted the family as far as a 2009 continuation (US 2009/0233808 A1, filed 2009-02-27, with US 7,517,643 from 11/187,989, filed 2005-07-22), which indicates active in-house management but no product application I can identify.
• Current status: Operating entity absorbed. On 2016-05-23 Arbor Pharmaceuticals (via parent Arbor Pharmaceuticals, LLC and purchaser AP Acquisition Sub, Inc.) agreed to acquire XenoPort in a ~$467 million cash tender offer/merger; the deal closed and was reported on Form 8-K 2016-07-05 ("Completion of Acquisition or Disposition of Assets"). Arbor funded roughly $467M from cash plus a Deutsche Bank debt commitment (up to $575M). No bankruptcy, no insolvency, no assignment for the benefit of creditors.
• Patent status: Google Patents records an adjusted expiration of 2023-01-20 with legal status "Expired – Fee Related." Any residual assertion value has lapsed.

Assignment timeline

There is one recorded assignment visible in the sources I retrieved. I explicitly could not retrieve reel/frame, execution date, or correspondent for it, and I have not invented them.

• Execution date not shown in retrieved sources / recorded 2001-05-11 — Reel not retrievable from the sources available to me
  • Conveyance: ASSIGNMENT OF ASSIGNORS' INTEREST (recorded description: "ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)")
  • Assignor: BARRETT, RONALD W.; CWIRLA, STEVEN E.; DOWER, WILLIAM J.; GALLOP, MARK; WOIWODE, THOMAS F. (all five named inventors, jointly)
  • Assignee: XENOPORT, INC.
  • Correspondent: not retrievable. Not a finding either way. For completeness, the prosecution attorney/firm of record on the printed patent is Townsend and Townsend and Crew LLP (post-2010 merger: Kilpatrick Townsend & Stockton LLP, West Coast), a general-practice IP firm serving many operating companies. That is prosecution counsel of record, not a confirmed assignment correspondent — I am not treating it as one.
  • Context: Original inventor-to-company assignment at formation/startup stage — the conventional founding-team assignment accompanying a 1999 provisional and 2000 non-provisional filing. Not a fire-sale, reorg, securitization, or transfer-to-asserter.
  • Repeat-correspondent flag: none available — a single recorded link with no correspondent data cannot establish recurrence.

No post-issuance assignment is reflected. Google Patents lists XenoPort, Inc. as both "Original Assignee" and "Current Assignee" — the same entity — and its legal-events list contains no assignment entry after 2001-05-11. This is consistent with (but not proof of) the 2016 transaction having been structured as a reverse triangular merger in which XenoPort, Inc. survived as a wholly owned subsidiary, so no deed of assignment was required to keep record title. I rate that inference medium confidence; confirming it would require reading the merger agreement's Section on assignment of intellectual property and checking whether a confirmatory assignment was ever recorded.

Family context (not assignments, but relevant to portfolio management): Google's event list shows priority to US 11/187,989 (2005-07-22) → US 7,517,643 B2 and to US 12/395,311 (2009-02-27) → US 2009/0233808 A1, both XenoPort family members. Neither entry is a transfer.

Cross-reference, different patent: XenoPort assignment reel 14069/164, executed 2003-04-25, recorded 2003-05-13, from Scheuerman, Gallop, Cundy and Barrett to XenoPort (US 7,183,259) — cited here only as evidence of continued inventor-to-XenoPort filings.

Timeline diagram

timeline
    title Ownership of US 7037706
    1999 : Provisional filed by five inventors
    2000 : Nonprovisional filed
         : Inventors assigned rights to XenoPort Inc
    2001 : Assignment recorded at USPTO
    2006 : Patent issued to XenoPort Inc
    2016 : Arbor Pharmaceuticals acquires XenoPort
         : XenoPort survives as subsidiary
    2023 : Adjusted patent term ends

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. The single recorded conveyance (recorded 2001-05-11) runs from the five inventors to XenoPort, Inc., a then-private operating biopharmaceutical company with a named California address and later SEC-registered status. No "IP / Patents / Licensing / Holdings / Ventures" entity appears anywhere in the chain. XenoPort is not a single-member LLC and no registered-agent-service address is involved.

2. Known asserter in the chain — NOT PRESENT. XenoPort does not match any public NPE list (Acacia, Marathon, Intellectual Ventures, IPNav, Wi-LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Erich Spangenberg entities, or Unified/RPX high-frequency plaintiff directories). It was a publicly traded, FDA-approved-product company. No evidence of this patent appearing in any asserted-patent list was surfaced.

3. Repeat correspondent across the chain — UNCLEAR (no data). I could not retrieve the recorded assignment correspondent for the 2001-05-11 entry; with only one recorded link there is no recurrence to measure in any event. Prosecution counsel of record (Townsend and Townsend and Crew LLP → Kilpatrick Townsend & Stockton LLP) is a large general-practice firm and is not being scored as an assignment correspondent. One appearance would not be a finding regardless.

4. Cascading transfers — NOT PRESENT. No chained LLCs; no successive assignments inside 24 months; strictly one recorded assignment in 2001, with no transfers at all in the 22 following years.

5. Pre-litigation transfer — NOT PRESENT. No infringement suit naming US 7,037,706 was surfaced in any source I retrieved, so there is no litigation trigger to time an assignment against. The 2001-05-11 recording predates issuance (2006-05-02) by five years, which is the opposite of a pre-suit standing-cleanup pattern.

6. Bankruptcy fire-sale — NOT PRESENT. XenoPort exited via a solvent $467M all-cash tender offer/merger consummated in July 2016 (Arbor Pharmaceuticals; debit financing from Deutsche Bank). There is no Chapter 7/11, no Section 363 sale, no Kodak/Nortel/Polaroid-style auction.

7. Privateering — NOT PRESENT. No operating-company-to-NPE transfer exists, and no assertion campaign on XenoPort's behalf was found. Notably, the claims cover a research-tool platform that XenoPort itself did not commercialize, so there was no competitor product driving a proxy assertion motive.

8. Defensive aggregator (anti-NPE) — NOT PRESENT. The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN. It terminates (by non-transfer) at XenoPort, Inc. and lapses on term expiry.

Additional neutral fact relevant to any enforcement theory: the patent's adjusted expiration is 2023-01-20 and its status is expired. Even a hypothetical later NPE chain would have nothing to assert today.

Verdict

Insufficient data.

The rubric assigns this verdict when the chain consists of only the original assignment, which is exactly the situation here: one recorded conveyance — the five inventors to XenoPort, Inc., recorded 2001-05-11, with no reel/frame or correspondent retrievable from my sources — and no post-issuance recording, with Google Patents showing the same entity as both original and current assignee. No NPE signal is present on any of the eight factors; the assignee is a venture-backed, then-Nasdaq-listed biopharmaceutical company that shipped a commercial product (HORIZANT), was acquired at a $467M valuation by Arbor Pharmaceuticals per the 2016-05-23 announcement and 2016-07-05 Form 8-K, and never appears on an NPE directory. The reservation is evidentiary, not substantive: because I could not open the Assignment Center record detail, I cannot rule out an unrecorded or later-recorded transfer (for example a confirmatory assignment tied to the 2016 merger), and I decline to speculate about it. Verification: search patent number 7037706 at the USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (mirror: https://assignment.uspto.gov/patent/index.html), and cross-check the legal events at https://patents.google.com/patent/US7037706/en. The Arbor transaction is documented in the SEC tender-offer materials at https://www.sec.gov/Archives/edgar/data/[1130591](/patent/1130591)/000119312516613379/d202436dex99a1a.htm.

Two open items to close the file: (a) the reel/frame, execution date, and recorded correspondent of the 2001-05-11 assignment; and (b) whether the 2016 Arbor merger produced any recorded confirmatory assignment from XenoPort, Inc.

I'll search for US 7,037,706 and, critically, its cited prior-art references (the front-page "References Cited" list), since the authoritative full text provided above does not include that section.

I found the front-page reference list, but the OCR of the U.S. patent numbers is garbled. Let me verify each cited patent individually.

Prior-Art Analysis — U.S. Patent No. 7,037,706

0. Flags before the substance

Two contradictions/housekeeping items I am obligated to surface:

1. Date conflict. The previously generated litigation section is dated 2026-09-27 ("Fetched: 2026-09-27"), while this task states April 26, 2026. The same patent is being analysed under two different "current dates." Nothing in the analysis below turns on this, but the record is internally inconsistent and should be reconciled.
2. Missing claim text. The authoritative full text supplied for this patent contains the abstract-equivalent "Definitions," the descriptions, and the drawing list — but no claims. A § 102 anticipation analysis is, strictly, a limitation-by-limitation comparison against issued claim language. I therefore cannot produce a certified "claim X is anticipated" mapping. What follows maps each cited reference to the claim concepts disclosed in the specification's Summary, and every claim-level statement is flagged PROVISIONAL.

I also note the operating rule against auto-correcting identifiers. Several patent numbers on the face of '706 are internally inconsistent (issue date does not match the number, and/or inventor name appears garbled). I reproduce them exactly as printed and flag the inconsistency rather than silently fixing them.

Identifier confirmation (literal): US 7,037,706 B1 — "Compounds displayed on replicable genetic packages and methods of using same." Inventors: Ronald W. Barrett, William J. Dower, Mark Gallop, Thomas F. Woiwode, Steven E. Cwirla. Original assignee: XenoPort, Inc. Application 09/675,525, filed 2000-09-29, granted 2006-05-02. Earliest priority asserted: 1999-09-29 (provisional 60/156,675, per the EPO publication record "29.09.1999 US 156675 P"). Prior art date on the face: 1999-09-29.

Source caveat. I queried web indexes that serve USPTO-derived data (Google Patents US7037706, FreePatentsOnline 7037706.html, uspto.report, and the granted-PDF text at patentimages). I could not run a native Patent Center / Patent Public Search / Patent Litigation Docket Report query in this session. Per the earlier litigation section, near-miss numerals ("7037706" as a Westlaw cite, a Japanese robot patent, a Venezuelan docket number) are not this patent and I have excluded them.

Governing law. Because the priority date is 1999-09-29, the pre-AIA version of 35 U.S.C. § 102 governs. Relevant sub-sections: § 102(a) (known/used/patented/published by others before the invention date); § 102(b) (patented or described in a printed publication more than one year before the U.S. filing date, i.e., before 1998-09-29); § 102(e) (U.S. patent granted on an application — or a PCT publication designating the U.S. and published in English — having an earlier effectively filed U.S. date). The AIA § 102(a)(1)/(a)(2) framework does not apply.

1. The "References Cited" list as it appears on the face of the patent

The Google Patents PDF text layer yields the following (OCR quality is poor on this section — the U.S. patent numbers/dates are partly inconsistent, and I could not re-image the page):

U.S. Patent Documents (exactly as printed):

Foreign Patent Documents (as printed): WO 93/11236 (6/1993); WO 97/10507 (3/1997); WO 98/15325 (11/1998); WO 98/51825 (11/1998); WO 01/05950 A2 (1/2001).

Other Publications (as printed): Brenner & Lerner, Encoded combinatorial chemistry, PNAS 89:5381–5383 (June 1992); Ellman & Gallop, Combinatorial chemistry—Editorial overview, Curr. Opin. Chem. Biol. 2:317–319 (1998); Armstrong et al., Orientation of the Virion During Assembly and Disassembly, IRL Press Ltd., 1641–1646 (1983); Chang et al., Subtiligase: A Tool for Semisynthesis of Proteins, PNAS 91:12544–12548 (1994); Cwirla et al., Peptides on Phage…, PNAS 87:6378–6382 (1990); Devlin et al., Random Peptide Libraries…, Science 249:404–406 (1990); Dwyer et al., Biosynthetic Phage Display…, Chem. & Biol. 7(4):263–274 (2000); Nakashima et al., Chemical Modification and Molecular Orientation of the B Protein in the Filamentous Bacterial Virus Pf1, J. Mol. Biol. 138:493–501 (1980); Sandman et al., Phage Display of Selenopeptides, JACS 122:960–961 (2000); Scott et al., Searching for Peptide Ligands with an Epitope Library, Science 249:386–390 (1990); Crameri et al., Display of Biologically Active Proteins on the Surface of Filamentous Phages…, Gene 137:69–75 (1993); Dente et al., Modified Phage Peptide Libraries…, J. Mol. Biol. 269(5):694–703 (1997); Maclean et al., Encoded combinatorial chemistry: synthesis and screening of a library of highly functionalized pyrrolidines, PNAS 94(7):2805–2810 (1997); Woiwode et al., Synthetic compound libraries displayed on the surface of encoded bacteriophage, Chem. & Biol. 10(9):847–858 (Sept. 2003).

On the asterisks: the OCR shows * next to 5,537,605, 5,958,703, 6,309,842 and 6,777,239. I do not have a verified decodable meaning for those marks from this record and will not assert one. Their only reliable signal here is that, paired with the "Other References" block, the list is evidently examiner-populated (mixed patent + NPL citations), not applicant-only.

On the "Claims" tags in the source page (e.g., "biotin — 0.000 claims description 118"): these are Google Patents keyword-density counters, not claims. They are not claim text.

2. Reference-by-reference analysis

A. References with verified identity

1. U.S. Patent No. 5,403,484 — Ladner et al., "Viruses expressing chimeric binding proteins"

• Full citation: US 5,403,484 A; Robert C. Ladner, Sonia K. Guterman, Bruce L. Roberts, William Markland, Arthur C. Ley, Rachel B. Kent; assignee Protein Engineering Corporation (Cambridge, MA); App. No. 08/009,319, filed Jan. 26, 1993; issued Apr. 4, 1995; 49 claims.
• Description: Randomises a "potential binding domain" and displays it as a chimeric protein on the outer surface of a "genetic package" — expressly bacteria, bacterial spores, or phage (M13) — via an outer-surface transport signal (e.g., M13 gene III). Packages displaying binders are selected by affinity to a target, then amplified and the successful domain sequenced. This is the foundational "replicable genetic package + surface display + selection + amplification + sequence readout" reference.
• § 102 mapping (PROVISIONAL):
  • Anticipates any independent claim that recites merely a replicable genetic package displaying a compound attached to an exterior surface group without the "other than an expressed polypeptide" limitation, and any claim to a method of (i) providing a variegated population of genetic packages displaying different moieties, (ii) selecting by affinity to a target, and (iii) recovering/identifying the displayed moiety. Ladner discloses each element, with the displayed moiety being a polypeptide.
  • Does not anticipate the '706 core claims, because the '706 Summary expressly limits the displayed compound to a compound other than an expressed polypeptide ("Certain of the replicable genetic packages display a compound other than a polypeptide…"). Ladner's disclosure is polypeptide display, i.e., outside that limitation. Similarly it does not reach claims requiring a heterologous nucleic acid tag that encodes a characteristic of the compound (Ladner's nucleic acid encodes the displayed protein itself, which the '706 specification expressly excludes: "a nucleic acid segment other than a segment that encodes for an expressed polypeptide displayed on the replicable genetic package").
  • Best posture: § 102(b) (issued more than one year before the 2000-09-29 filing; and 1995 < 1998-09-29).

2. U.S. Patent No. 5,723,598 — Lerner, Janda & Brenner, "Encoded combinatorial chemical libraries"

• Full citation: US 5,723,598; Richard Lerner, Kim Janda, Sydney Brenner; assignee The Scripps Research Institute; App. No. 08/665,511, filed June 18, 1996 (divisional of 07/860,445, now US 5,573,905); issued Mar. 3, 1998.
• Description: Bifunctional molecules A–B–C in which A is a chemical polymer (polypeptide, oligosaccharide, glycolipid, glycopeptide, sulfonamide, etc.), B is a linker, and C is an identifier oligonucleotide that encodes the structure of A built by alternating parallel combinatorial synthesis with split/pool. Includes: non-natural amino acids; PCR primer-flanked identifiers; a "commaless" code and other encodings not the standard genetic code; affinity selection of the library against a biologically active molecule; decoding by PCR/cloning/sequencing or by hybridisation enrichment with a probe; and linker chemistries. This is the seminal "encoded combinatorial library" patent.
• § 102 mapping (PROVISIONAL):
  • Anticipates any claim whose gist is a library of compounds, each attached through a linker to a nucleic acid tag that encodes the compound's structure (including by a code other than the standard genetic code), and methods of screening/decoding such a library. In particular, the '706 Summary's concept of a tag that "encodes… the specific structural identity of the compound" or "a value or symbol assigned to the compound," and of encoding "by a code other than the standard genetic code," is disclosed in substance by Lerner (the specification's commaless-code passage is squarely anticipated by Lerner's commaless-code disclosure).
  • Does not anticipate claims limited to (i) the compound being displayed on a replicable genetic package (Lerner's entities are free bifunctional molecules — not phage, bacteria, spores or cells), or (ii) amplification of the tag in vivo/via the package.
  • Best posture: § 102(b) (issued 1998 but the underlying disclosure published earlier; the parent US 5,573,905 issued Nov. 12, 1996, and the family's WO 93/20242 published Oct. 14, 1993 — squarely before 1998-09-29). If the examiner used the "Parent Case Text" route, the parent US 5,573,905 (Nov. 12, 1996) would be the cleanest § 102(b) citation for the identical disclosure.

3. Brenner & Lerner, Encoded combinatorial chemistry, PNAS 89:5381–5383 (June 1992)

• Description/§ 102: The non-patent sibling of Lerner '598 — the "retrogenetic"/encoded-library concept: alternating peptide + oligonucleotide-tag synthesis, split-pool, selection, PCR amplification, hybridisation enrichment. § 102(b) (June 1992 ≪ 1998-09-29). Directly anticipates any claim drawn to encoding a chemical compound's identity in an amplifiable nucleic acid tag attached through a linker.

4. Cwirla et al. (PNAS 87:6378–6382, 1990); Scott et al. (Science 249:386–390, 1990); Devlin et al. (Science 249:404–406, 1990); Crameri et al. (Gene 137:69–75, 1993); Dente et al. (JMB 269:694–703, 1997); Maclean et al. (PNAS 94:2805–2810, 1997)

• Description: The classic phage-display peptide-library triad (random peptides fused to pIII/pVIII of filamentous phage, affinity selection, sequence decode), plus protein display (Crameri), modified phage peptide libraries (Dente), and the encoded pyrrolidine small-molecule library with a chemical (not genetic) code (Maclean, 1997).
• § 102 mapping (PROVISIONAL): All are § 102(b) art as to the filing date. Cwirla/Scott/Devlin anticipate claims to replicable genetic packages displaying different foreign sequences and methods of selecting them by affinity — but again their displayed entities are expressed polypeptides, so they do not reach the "compound other than an expressed polypeptide" limitation. Maclean et al. (1997) is the most dangerous of this group for the non-polypeptide aspects: an encoded library of highly functionalised small molecules (pyrrolidines) with an identifier code, decoded after selection. It anticipates claims to encoded small-molecule libraries and their screening/decoding; it does not disclose display on a replicable genetic package (the molecules are on solid-phase beads).

5. Armstrong et al. (1983); Nakashima et al. (J. Mol. Biol. 138:493–501, 1980); Chang et al. (PNAS 91:12544–12548, 1994)

• Description/§ 102: Virion assembly/orientation (Armstrong, Nakashima) and enzymatic semisynthesis of proteins via subtiligase (Chang). These are background/mechanics references (§ 102(b) for the 1980/1983 items; Chang 1994 also § 102(b)). They do not, individually, disclose a compound-bearing replicable genetic package and typically would have been cited to show the state of coat-protein/linker chemistry. Unlikely to anticipate any independent claim; potentially relevant only to narrow dependent claims (e.g., attachment chemistry, semi-synthetic conjugation).

6. Ellman & Gallop (Curr. Opin. Chem. Biol. 2:317–319, 1998)

• Description/§ 102: Editorial overview of combinatorial chemistry (co-authored by a named '706 inventor, Mark Gallop). § 102(b) as a printed publication (>1 yr before 2000-09-29), but it is a review, not an enabling disclosure of the packages claimed; at most § 103 context. Not an anticipation reference.

7. Woiwode et al., Synthetic compound libraries displayed on the surface of encoded bacteriophage, Chem. & Biol. 10(9):847–858 (Sept. 2003)

• Description/§ 102 — SPECIAL NOTE: This is the inventors' own later publication describing the very work of the '706 patent. It post-dates the 1999-09-29 priority date by four years. It cannot be prior art under § 102(a) or (b) against the '706 claims (and is not "by another"). Its presence on the face of the patent is consistent with an applicant-supplied list of the inventors' own journal coverage. Do not treat as invalidating art.

B. References whose identity I could NOT verify — flagged

For the following I could not confirm title, assignee, or filing date within this session. I give the printed citation and a conditional § 102 posture, and I explicitly decline to assert a title:

On the two post-2001 Dower patents (6,309,842; 6,777,239): if they are grants on applications filed before 1999-09-29, the examiner would properly have cited them under pre-AIA § 102(e) (subject to the Hilmer doctrine if they claim foreign priority — a foreign priority date does not count for § 102(e)). If they are "by another" and commonly owned, they remain available for anticipation under § 102(e); the § 103(c) safe harbour protects them only from obviousness combinations. I could not verify either filing date in this session — verify before relying on them.

C. Foreign references

3. Most relevant prior art — ranked

1. US 5,723,598 (Lerner et al.) / US 5,573,905 (parent) and Brenner & Lerner, PNAS 89:5381–5383 (1992) — the strongest art on the encoding half of the invention: linker-attached nucleic acid tags that encode a chemical compound's structure, including non-genetic codes, with selection and PCR/hybridisation decoding. The '706 specification's own "code other than the standard genetic code" concept and its "tag encodes a value or symbol assigned to the compound" concept are squarely within Lerner's disclosure. Best § 102(b) posture (1992–1996).
2. US 5,403,484 (Ladner et al.) — the strongest art on the display-package half: bacteria/spore/phage "genetic packages" displaying foreign moieties on the exterior, selected by affinity, recovered, and identified. Fails only on the '706 limitation that the displayed compound be other than an expressed polypeptide.
3. Maclean et al., PNAS 94(7):2805–2810 (1997) — controlled small-molecule (pyrrolidine) encoded library with selection and decoding; attacks the "small molecule, not a peptide" rationale but lacks the replicable-package display element.
4. Cwirla/Scott/Devlin (1990) — the canonical phage-display library art; § 102(b), but polypeptide-only.
5. US 5,958,703, US 5,639,603, US 6,309,842, US 6,777,239 (all Dower et al.) — potentially the most practically dangerous if any of them has an effective pre-1999 filing date, because they are the same lineage as the '706 inventors (Affymax/XenoPort). Same-inventor and common-ownership status must be checked against the '706 inventive entity before asserting § 102.
6. WO 01/05950 A2 — worth checking first as a possible § 102(e) reference with a mid-1999 international filing date.

4. Limitations of this analysis (read before relying on it)

1. No claim text was retrievable. Every claim-level statement above is PROVISIONAL and is keyed to claim concepts in the '706 specification (Summary of the Invention), namely: (i) a replicable genetic package displaying a compound other than an expressed polypeptide; (ii) optionally harbouring a heterologous nucleic acid tag encoding a characteristic of the compound; (iii) attachment via a linker (package linker and/or compound linker, including binding-pair members); (iv) multiple/same-or-different compounds; (v) libraries of such packages, including isothermal tags of the same base composition; and (vi) screening methods (in vitro, in vivo, transcytosis/transport, pooling schemes, probe-based decoding).
2. Six of eleven cited U.S. patents could not be verified by title/filing date in this session, and two of them (5,537,605 and 5,587,500) are internally date/number-inconsistent as printed. I did not correct them.
3. "§ 102(e) candidates" (6,309,842; 6,777,239; 6,027,890; 6,057,098; WO 01/05950) cannot be finally assessed without their underlying U.S. filing dates, international filing dates, and (for the Dower patents) a same-inventor / common-ownership check against the '706 inventive entity.
4. Post-priority NPL (Dwyer 2000; Sandman 2000) is § 102(a)-only at best (published after 1999-09-29 but arguably before the invention date) and is antedatable under Rule 131; the Woiwode 2003 paper is the inventors' own work and is not prior art.

Recommended verification steps (none of which I could execute here): pull the front-page "References Cited" and the full claim set from USPTO Patent Public Search / Patent Center; obtain each cited patent's filing/priority date and inventive entity/assignee from Patent Center or Global Dossier; run the USPTO Patent Litigation Docket Report (35 U.S.C. § 290) and the PTAB "Post-Grant" tab (per the earlier section, none identified); and confirm WO 01/05950's international filing date via PATENTSCOPE.

I'll first try to retrieve the actual prior-art reference list for this patent, since the page text supplied above includes only "Prior art keywords" and CPC classes — not the enumerated references.

Let me pull the full cited-reference list and the actual claim language.

Obviousness Analysis — U.S. Patent No. 7,037,706 (Barrett et al.) under 35 U.S.C. § 103

0. Source note (read first)

The page text supplied to me for this patent contains a "Prior art keywords" block (bacteriophage; compound; phage; compounds; linker) and the CPC classifications (C40B40/02; C12N15/1034; C12N15/1037), but it does not reproduce the enumerated "References Cited" list, the Office Actions, or the full claim set. To do this analysis I retrieved the granted-patent front page and claim excerpts from the record. Where I state what a reference discloses, I distinguish (a) what I could verify from the retrieved text, from (b) what I am inferring from a title/date. Nothing below should be read as a certified prior-art clearance.

Sources used:

• Google Patents record (as supplied): https://patents.google.com/patent/US7037706/en
• Granted-patent front page / references cited: https://patentimages.storage.googleapis.com/ac/39/66/4b0fd46427ef1c/US7037706.pdf and https://www.freepatentsonline.com/7037706.html
• Claim excerpts (claims 8–11, 20, 32–34, 36 and one independent claim): https://patents.justia.com/patent/7037706
• Family/PCT counterpart claims: https://patents.google.com/patent/WO2001023619A1/en

1. Legal framework and critical date

• The application is pre-AIA: filed 2000-09-29, priority 1999-09-29, granted 2006-05-02, now Expired – Fee Related (adjusted expiration 2023-01-20). Sections 102(a)/(b)/(e) and 103(a) apply as written before the AIA, and KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007), governs the § 103 analysis.
• Presumptive critical date for § 102(b) art: 1998-09-29. Anything published on/after 1999-09-29 is presumptively not prior art.
• The patent is expired and (per the accompanying litigation section) was never litigated, so there is no claim construction to rely on. My reading is effectively a broadest-reasonable-interpretation reading of the retrieved claim text.

1.1 Status of the cited references — an important filtering step

Consequence: the three references most embarrassing to the patent's premise — Dwyer (biosynthetic phage display combining chemical and genetic diversity), Sandman (phage display of selenopeptides), and the inventors' own Woiwode 2003 paper — are all post-priority and cannot support a § 103 rejection. The rejection case must therefore be built from the 1980–1998 art (Ladner, Lerner, Dower, Cwirla, Devlin, Scott & Smith, Brenner & Lerner, Maclean, Nakashima, Crameri, Ellman & Gallop).

2. The claim set as it can be reconstructed

From the retrieved excerpts, the issued claims are bacteriophage-limited, not generic to "replicable genetic packages":

• Independent claim (bacteriophage displaying a non-expressed-polypeptide compound + decodable heterologous tag): "A bacteriophage displaying a compound other than an expressed polypeptide, wherein the bacteriophage and the compound are attached via a linker, and wherein the bacteriophage comprises a heterologous nucleic acid tag that can be decoded to identify a characteristic of the compound and the heterologous nucleic acid tag is a nucleic acid segment other than a segment that encodes for a polypeptide displayed on the bacteriophage."
• Separate independent claim: a replicable genetic package (in the family's PCT text, claim ~26/40 of WO 2001023619A1) "wherein the replicable genetic package comprises a heterologous nucleic acid tag encoding a characteristic of the compound by a code other than the standard genetic code."
• Claim 8: covalent attachment via an endogenous functional group on the bacteriophage and a functional group on the compound.
• Claim 9: package linker. Claim 10: compound linker. Claim 11: both linkers, associated.
• Claim 20: plurality of displayed compounds.
• Claim 32: tag encodes compound identity. Claim 33: tag encodes a value or symbol assigned to the compound.
• Claim 34: tag flanked by a heterologous promoter and a heterologous restriction site, promoter operably linked to the tag.
• Claim 36: collection of bacteriophages, different compounds / different tags.
• Plus method claims (screening; transport through cells) whose individual numbers I could not retrieve.

The single point of novelty across all of this is the substitution of a chemically synthesized, non-polypeptide compound for the genetically encoded peptide of classical phage display, while retaining a genotype/phenotype-like linkage implemented by a tag that does not encode the displayed moiety. Everything else in the claims (linkers, binding pairs, multivalency, collections, screening, decoding by sequencing/hybridization) is conventional combinatorial-chemistry and molecular-biology machinery.

3. Element-by-element mapping

Caveat: the "isothermal tags which have the same base composition" limitation appears only in the specification summary; the encoding scheme of Brenner & Lerner (1992) is generally understood to employ fixed-length tags of uniform base composition so that all tags share hybridization behavior, which would render that limitation obvious — but I could not retrieve the full text in this session to verify that teaching, so I flag it as unverified rather than assert it.

4. The three strongest § 103 combinations

Combination A (primary): Lerner US 5,723,598 + Ladner US 5,571,698 (or Cwirla 1990 / Scott & Smith 1990)

Where each teaches: Lerner '598 (with Brenner & Lerner 1992 as its enabling publication) teaches synthesizing non-peptidic combinatorial libraries in which each library member carries a decodable nucleic acid tag that does not encode that member — the tag is a record, not a translation product. Ladner '698 and Cwirla teach a replicable biological particle (phage) that can be selected by affinity, amplified, and traced to a nucleic acid sequence carried inside it.

Motivation (KSR factors 1, 2, 3, 4): Both references are in the same field (combinatorial drug discovery / library screening) and address the same problem (how to identify, from a large library, the one member with a desired activity, at single-molecule sensitivity). A POSA would have recognized that the solid-phase bead of Lerner's encoded chemistry is functionally interchangeable with a phage particle as the "support" for a tagged library member, with the added, predictable advantage that the phage can be amplified rather than read out by physical sorting. Substituting one known library-support vehicle for another, where both are known to work and the substitution merely improves throughput, is the paradigmatic "predictable variation" case. The only remaining difference — that the library member is attached to rather than synthesized on the support — is taught as an available option in the same art (hapten conjugation to carrier proteins and to virions).

Combination B: Maclean 1997 + Cwirla 1990 (or Scott & Smith 1990)

This is the tightest pairing because Maclean 1997 is an actual reduction to practice of exactly the missing element: an encoded library of non-peptidic, highly functionalized pyrrolidines, screened, and decoded via the tag. Cwirla/Scott & Smith supply the replicable-package platform with an established selection/amplification protocol. Rational motivation: Maclean's bead-based readout requires sorting and physical handling; the phage platform of Cwirla was known to permit affinity enrichment with amplification, which a POSA seeking higher sensitivity and lower screening burden would have been motivated to adopt. There is no teaching away in either reference: neither disparages particles as supports, and neither requires the library member to be genetically encoded.

Combination C (chemical-enabling reference): Nakashima 1980 (or Armstrong 1983; Chang 1994) + Combination A or B

The anticipated objection is that phage particles are fragile and that chemical derivatization destroys infectivity — i.e., no reasonable expectation of success. Nakashima 1980 directly defeats that objection: it teaches chemical modification of a filamentous virion coat protein while tracking protein orientation, establishing that virion surface chemistry is tractable. Armstrong 1983 corroborates the accessibility/orientation of coat proteins in assembled virions, and Chang 1994 shows enzymatic (rather than purely chemical) elaboration of proteins. With that disclosure in hand, a POSA would have had a reasonable expectation that NHS-ester (lysine), maleimide/iodoacetamide (cysteine), carbodiimide (amine/carboxyl) and hydrazide (aldehyde) conjugations — all textbook bioconjugation chemistries by 1999 — could be performed on phage coat proteins, with routine optimization of stoichiometry and pH. The patent's own Examples 11–22 (biotin, fluorescein, dansyl, BODIPY and Texas Red conjugations, with titer measurements before/after) are consistent with this being routine optimization rather than invention.

Net result: Combination A or B supplies every limitation of the independent bacteriophage claim; Combination C removes the only credibility-based objection to practicing it. Claims 8–11, 20, 32, 33, 36 and the method claims add only conventional features.

5. The method claims (screening, transport)

For the transport-screening species (transwell monolayer of polarized cells over an impermeable membrane; retrieval from tissue/body fluid after in vivo administration):

• The transwell/Caco-2-type monolayer format was a standard, well-known in vitro model for epithelial permeability well before 1999, and the patent does not describe a non-conventional configuration of it.
• The in vivo retrieval species is the in vivo phage-display paradigm (administration of a phage library to an animal, recovery from a tissue, identification of the retrieved clone by sequencing the recovered genome), which was established prior art. Combined with Combinations A/B, the transformation of that platform from peptide-displaying phage to chemically-conjugated-compound-bearing phage is a mechanical substitution.
• Motivation: selecting for transport rather than binding is a change in the selection criterion, not in the mechanism of the assay, and both criteria were known targets of phage library screens.

6. Where a nonobviousness argument could still be made

A competent response to any of the above rejections would press these points, and they are not frivolous:

1. Hindsight in the combination. The prior art encodes in vitro-synthesized libraries on beads (Brenner & Lerner; Maclean) and displays in vivo-synthesized peptides on phage (Cwirla; Ladner). Neither line proposes putting a chemically synthesized compound onto a living, replicable particle. The "substitution of support" characterization is easier to assert after reading the specification than it was in 1999.
2. The 1:1 correspondence problem. As the family's later specification itself concedes (US 20090233808A1, ¶ discussing the "several challenges"), establishing a unique 1:1 correspondence between a chemically synthesized library member and a clonal phage isolate, without compromising infectivity, is a genuine practical hurdle. If the applicant can show the art lacked a workable attachment regime, that supports nonobviousness of the enabled combination — although under KSR a "finite number of identified, predictable solutions" argument cuts the other way.
3. A specific teaching away. If any 1993–1998 reference states that the phage coat cannot tolerate chemical derivatization without loss of infectivity, that must be produced and weighed. The cited art I verified (Nakashima 1980) cuts against such a teaching away.

Secondary considerations: the record I retrieved contains no evidence of unexpected results, long-felt need, licensing, or industry praise tied to the '706 claims. The inventors' own Woiwode 2003 paper is a reduction-to-practice report, and it is not prior art — but it is also not evidence of unexpected results, since the reported outcome (compounds displayed on encoded bacteriophage) is the expected outcome of the proposed combination.

7. Bottom line and confidence

• Strongest rejection theory: Maclean 1997 (non-peptidic, nucleic-acid-encoded combinatorial library) + Cwirla 1990 or Ladner US 5,571,698 (replicable-phage display with selection and amplification) + Nakashima 1980 (chemical modification of virion coat proteins is feasible without destroying the particle).
• Alternative theory: Brenner & Lerner 1992 / Lerner US 5,723,598 + Scott & Smith 1990 + Devlin 1990, plus Ellman & Gallop 1998 for the state of combinatorial chemistry.
• Likely claim outcome: the independent claims and dependent claims 8–11, 20, 32–34 and 36 appear obvious over these combinations; the method claims appear obvious over the same combinations plus routine assay formats. The narrow "isothermal tags / same base composition" limitation is the only element I could not map with confidence.
• Confidence: moderate-to-high on the reference-level reasoning; moderate on completeness, because (i) the supplied page has no enumerated prior-art list, (ii) I could not retrieve the full claim set or the prosecution history, and (iii) I could not verify the disclosure content of the Lerner, Dower, Krebber, Ness, Buechler and WO references beyond titles and dates. A conclusion-grade obviousness opinion would require the full IDS, the file history, and the full texts of US 5,723,598, US 5,571,698, US 5,639,603, WO 93/11236, WO 97/10507, WO 98/15325 and WO 98/51825.
• Contradiction check: nothing in this analysis contradicts the previously generated litigation section. That section's finding — no litigation, patent expired 2023-01-20, no PTAB/ITC/reexamination activity — is consistent with the file history used here; the absence of litigation also means no court has construed these claims, which is why the mapping above is stated in terms of the plain claim language rather than a construction.